CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  
Response to consultation

DATE  
2017-06-28

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Jun 13, 2017

To Whom It May Concern

The Canadian Medical Association (CMA) is pleased to provide the comments of its members to Health Canada’s Federal Medicines, Regulations Consultations. The CMA is a national voice of Canadian physicians. Recognized as such, we are in a unique position to comment on private drug sectors for patients. The CMA is a voluntary professional organization representing the medical profession of Canada. Its members are engaged in maintaining and advancing the services of health care to patients.

In the scenario that the total health expenditures in Canada. For example, the cost of drug is at significant concern for physicians. In 2004, the cost of pharmaceutical drug spending 41.5 billion dollars in the United States. Pharmacists and physicians are concerned about the increase in drug prices, especially for patients with chronic diseases. The cost of drug has been a significant concern for patients and physicians. The CMA has called for a public health system of accessible coverage for prescription drugs. We believe that an effective and efficient health care system with accessible coverage for prescription drugs is essential to ensure the health and well-being of Canadians.

CMA Policybase - Canadian Medical Association